This is a blind, placebo controlled, crossover study of the efficacy of single intravenous doses of a potent and selective antagonist of a novel NMDA subclass of glutamate receptors. It has been discontinued due to concerns over mild and reversible central nervous toxicity noted in normal volunteers.
Showing the most recent 10 out of 675 publications